Lung injury following cardiopulmonary bypass: a clinical update.


Journal

Expert review of cardiovascular therapy
ISSN: 1744-8344
Titre abrégé: Expert Rev Cardiovasc Ther
Pays: England
ID NLM: 101182328

Informations de publication

Date de publication:
Nov 2022
Historique:
pubmed: 22 11 2022
medline: 15 12 2022
entrez: 21 11 2022
Statut: ppublish

Résumé

Cardiopulmonary bypass (CPB) is an integral component of cardiac surgery; however, one of its most critical complications is acute lung injury induced by multiple factors including systemic inflammatory response. The objective of this review is to investigate the multiple factors that can lead to CPB-induced lung injury. These include contact of blood components with the artificial surface of the CPB circuit, local and systemic inflammatory response syndrome (SIRS), lung ischemia/re-perfusion injury, arrest of ventilation, and circulating endotoxins. We also focus on possible interventions to curtail the negative impact of CPB, such as off-pump surgery, impregnation of the circuit with less biologically active substances, leukocyte depletion filters and ultrafiltration, and pharmacological agents such as steroids and aprotinin. Although many aspects of CPB are proposed to contribute to lung injury, its overall role is still not clear. Multiple interventions have been introduced to reduce the risk of pulmonary dysfunction, with many of these interventions having shown promising results, significantly attenuating inflammatory mediators and improving post-operative outcome. However, since lung injury is multifactorial and affected by inextricably linked components, multiple interventions tackling each of them is required.

Identifiants

pubmed: 36408601
doi: 10.1080/14779072.2022.2149492
doi:

Substances chimiques

Inflammation Mediators 0

Types de publication

Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

871-880

Auteurs

Georgios Nteliopoulos (G)

Department of Surgery and Cancer, Imperial College London, London, UK.

Zacharoula Nikolakopoulou (Z)

Department of Department of Immunology and Inflammation, Centre for Haematology, Imperial College London, London, UK.

Bobby Hiu Nam Chow (BHN)

Division of Cardiovascular Sciences, University of Manchester, Manchester, UK.

Rebecca Corless (R)

Evexia Healthcare Solutions, Manchester, UK.

Bao Nguyen (B)

Department of Cardiothoracic Surgery, Derriford Hospital, Plymouth, UK.

Ioannis Dimarakis (I)

Division of Cardiovascular Sciences, University of Manchester, Manchester, UK.
Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Wythenshawe Hospital, Manchester, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH